



Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics

Cambridge, UK – 28 September 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody® therapeutics, has been granted U.S. patent No. 9,439,405 to its novel transgenic mouse platform (Crescendo Mouse) for generating Humabody® drug products.

The patent covers mice which do not produce functional endogenous antibody lambda light chains due to deletions in the lambda light chain locus. This is a key component of the Crescendo Mouse which produces fully human V_H domains in a proprietary ‘triple knockout’ background devoid of mouse antibodies. This means that V_H domains are affinity matured *in vivo* in the absence of any contaminating endogenous antibody light chains and as such are naturally filtered for highly attractive biophysical properties.

Based on these robust Humabody® building blocks, Crescendo is able to rapidly assemble an almost limitless number of multispecific configurations. Crescendo can then identify optimal formats for engaging therapeutically valuable targets in a way that is fundamentally different than using whole Immunoglobulins.

Barbara Fleck, Head of IP of Crescendo Biologics, commented:

“This important piece of IP further strengthens our patent portfolio. We have built an exceptionally powerful platform for the generation of fully human V_H domains which provide robust building blocks for the generation of mono- and multi-specific Humabody® products.”

Dr Peter Pack, CEO of Crescendo Biologics, said:

“We are building a pipeline of differentiated, potent therapeutics of minimal size that leverages our proprietary technology platform. We are seeking to address the issues of current biologics based on conventional IgGs with rapidly configured multi-specific Humabody® therapeutics.

“Our design is based on fully human V_H building blocks from our transgenic mouse without the inherent risks of artificial scaffolds. This results in improved therapeutic index options which we combine with excellent potency and druggability.”

--End--

Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company involved in discovering and developing potent, highly differentiated Humabody® therapeutics with a focus on cancer. The Company’s Humabody® therapeutics are based on its proprietary, robust and highly efficient fully human V_H domain technology platform.

Crescendo is building a pipeline of new differentiated medicines, including Humabody® Drug Conjugates (HDCs) and multi-specific immuno-oncology (IO) modulators, through in-house development and strategic partnerships.

Crescendo’s technology platform is centred on a unique and proprietary transgenic mouse, which enables the benefits of *in vivo* maturation to be harnessed thereby naturally optimising the affinity and biophysical properties of Humabody® products. Compared with monoclonal antibodies,



Humabody® therapeutics offer a unique combination of potential benefits that results from their small size, cost-effective production and modular plug & play engineering options for generating novel bi- or multi-specific formats.

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Imperial Innovations, Astellas Venture Management and EMBL Ventures.

For more information, please visit the website: www.crescendobiologics.com

For more information, please contact:

Crescendo Biologics

Dr Peter Pack, CEO

Tel:44 (0)1223 497140

info@crescendobiologics.com

Instinctif Partners

Melanie Toyne-Sewell / Dr Christelle Kerouedan

Tel:44 (0)20 7457 2020

crescendo@instinctif.com